OGA INHIBITOR COMPOUNDS

The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatmen...

Full description

Saved in:
Bibliographic Details
Main Authors LEENAERTS, Joseph Elisabeth, TRABANCO-SUÁREZ, Andrés, Avelino, BARTOLOMÉ-NEBREDA, José Manuel, VELTER, Adriana Ingrid, BUIJNSTERS, Petrus Jacobus Johannes Antonius, VAN ROOSBROECK, Yves Emiel M, MARTINEZ LAMENCA, Carolina, OEHLRICH, Daniel, DE LUCAS OLIVARES, Ana Isabel
Format Patent
LanguageEnglish
French
German
Published 26.10.2022
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.
Bibliography:Application Number: EP20200838041